{
    "clinical_study": {
        "@rank": "168235", 
        "arm_group": {
            "arm_group_label": "HEPLISAV", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will investigate the response of the immune system to a hepatitis B vaccine in\n      healthy adults 50 to 70 years of age.  This study is partially funded by the National\n      Institute of Allergy and Infectious Diseases."
        }, 
        "brief_title": "A Study of the Immune Response to Heplisav in Healthy Older Adults", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to examine how the immune system responds to vaccination with\n      HEPLISAV."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  50 to 70 years of age, inclusive\n\n          -  In good health in the opinion of the principal investigator, based upon medical\n             history and physical examination\n\n          -  Serum negative for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc),\n             hepatitis C virus (HCV), and human immunodeficiency virus (HIV)\n\n          -  If female of childbearing potential, agree to consistently use a highly effective\n             method of birth control from the screening visit through Week 12/Visit 10\n\n        Exclusion Criteria:\n\n          -  Pregnant, breastfeeding, or planning a pregnancy\n\n          -  Known history of an autoimmune disease\n\n          -  Previously received any hepatitis B vaccine (approved or investigational)\n\n          -  Body-mass index (BMI) >30 kg/m2, diabetes mellitus (type 1 or 2), or other chronic\n             medical condition that in the opinion of the principal investigator might interfere\n             with the immune response to hepatitis B vaccination"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999699", 
            "org_study_id": "DV2-HBV-22"
        }, 
        "intervention": {
            "arm_group_label": "HEPLISAV", 
            "intervention_name": "HEPLISAV", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Heplisav", 
        "lastchanged_date": "December 2, 2013", 
        "link": {
            "url": "http://www.dynavax.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }, 
                "name": "Johnson County Clinical Trials"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.", 
        "overall_official": {
            "affiliation": "Dynavax Technologies Corporation", 
            "last_name": "Robert Janssen, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Evaluate the changes in cellular responses and gene expression patterns in serial blood samples collected from healthy older adults after vaccination with HEPLISAV.", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 3, and 7 and on Day 28"
            }, 
            {
                "measure": "Determine which of these changes correlate with the development of protective levels of antibody (anti-HBs >/= 10 mIU/mL) to HBV.", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 3, and 7 and on Day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999699"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dynavax Technologies Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Baylor Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Dynavax Technologies Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}